Epstein Secrets

in NYC. Best Regards, James Dear James, Like I have said in an earlier email. I am looking for an "investing partner" to match (50%/50%) the money Russian Venture Capital plans to invest in USA based Biotechnology. They will provide half of the capital to develop a variety of technologies that are of interest to their

logies that are worthy of development. RVC has already agreed to finance the first (MAR) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

in NYC. Best Regards, James Dear James, Like I have said in an earlier email. I am looking for an "investing partner" to match (50%/50%) the money Russian Venture Capital plans to invest in USA based Biotechnology. They will provide half of the capital to develop a variety of technologies that are of interest to their

ogies that are worthy of development. RVC has already agreed to finance the first (MALI) and is looking at the next two—Prediction Biosciences, and OvationBio. I have several more currently in diligence. (The original Investor Presentation made in Moscow is attached) So, I am looking for a source of capit

cal need to reduce the 45% failure rate of coronary artery by-pass grafts. This is a major unmet medical need in both Russia and the United States. Russian Venture Capital has agreed to provide approximately half of the capital ($3.0M) to launch MALI in its Series A Round. I need to find the matching approximate $3.5M.

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

cal need to reduce the 45% failure rate of coronary artery by-pass grafts. This is a major unmet medical need in both Russia and the United States. Russian Venture Capital has agreed to provide approximately half of the capital ($3.0M) to launch MAJI in its Series A Round. I need to find the matching approximate $3.5M.

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges

cal need to reduce the 45% failure rate of coronary artery by-pass grafts. This is a major unmet medical need in both Russia and the United States. Russian Venture Capital has agreed to provide approximately half of the capital ($3.0M) to launch MAJI in its Series A Round. I need to find the matching approximate $3.5M.

ly. It will be a challenge to find investors, sensitive to risk and return, to provide OvationBio the capital it needs to do its early work. Somehow OvationBio is what I thought you would find most interesting. Producing polyclonal antibodies from genetically modified chickens could solve one of the bigges